MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. (Q37635027)
Jump to navigation
Jump to search
scientific article published on 27 August 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. |
scientific article published on 27 August 2013 |
Statements
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program (English)
Zijun Y Xu-Monette
Wenwei Hu
Ganiraju C Manyam
Louise Kristensen
Lei Fan
Carlo Visco
April Chiu
Wayne Tam
Youli Zu
Kristy L Richards
Eric D Hsi
William W L Choi
Qin Huang
Jooryung Huh
Weiyun Ai
Maurilio Ponzoni
Andrés J M Ferreri
Lin Wu
Xiaoying Zhao
Carlos E Bueso-Ramos
Sa A Wang
Yong Li
Miguel A Piris
L Jeffrey Medeiros
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference